What deals did the Trump administration strike on GLP-1 prices?
November 2025 deals with Lilly and Novo tied Medicare/Medicaid prices to the lowest abroad at $245/month, opened obesity coverage with $50 copays, and reportedly gave manufacturers a three-year tariff exemption — but pharmacy groups questioned how headline discounts compare with plans' existing net prices.
In November 2025 President Trump announced agreements with Lilly and Novo tying prices to the lowest paid abroad. Under the deals, Medicare and Medicaid prices for Ozempic, Wegovy, Mounjaro and Zepbound would be $245 a month, Medicare would cover Wegovy and Zepbound for obesity with related conditions for the first time, and beneficiaries would pay $50 copays. Cash prices on the new TrumpRx.gov site would start at $350 a month and trend down to $245 over two years, with oral versions priced lower. The companies reportedly received a three-year tariff exemption. Earlier, in April 2025, the administration had declined to finalise a Biden-era rule for Medicare obesity-drug coverage. Pharmacy groups noted it was unclear how headline discounts compare with net prices plans already pay.